A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients

Massive expansion of regulatory T-cells following interleukin 2 treatment during a phase I-II dendritic cell-based immunotherapy of metastatic renal cancer

(2009) Lemoine   INTERNATIONAL JOURNAL OF ONCOLOGY

Topical imiquimod and intralesional interleukin-2 increase activated lymphocytes and restore the Th1/Th2 balance in patients with metastatic melanoma

(2008) D.S. Green et al.   BRITISH JOURNAL OF DERMATOLOGY

Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers

(2008) Antoun Toubaji et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

T Regulatory Type 1 Cells in Squamous Cell Carcinoma of the Head and Neck: Mechanisms of Suppression and Expansion in Advanced Disease

(2008) C. Bergmann et al.   CLINICAL CANCER RESEARCH

Development of multi-epitope vaccines targeting wild-typesequence p53 peptides

(2008) Albert B DeLeo et al.   Expert Review of Vaccines

Immunosuppression induced by immature dendritic cells is mediated by TGF-β/IL-10 double-positive CD4+regulatory T cells

(2008) N. Cools et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE